April–June 2026
CS MEDICA A/S ("CS MEDICA") reports its Q3 results for April–June 2026. Previously delayed orders progressed into production and invoicing, including a significant white-label delivery to an established European partner. Combined with the reduced cost base, this resulted in the highest quarterly gross profit and the lowest operating loss of the financial year so far.
Q3 2025/2026
- Revenue: DKK 2.9 million (Q2 2025/2026: DKK 0.3 million)
- Gross profit: DKK 1.7 million (Q3 2024/2025: DKK 0.6 million), gross margin 60%
- Operating result (EBIT): DKK -0.4 million (Q3 2024/2025: DKK -1.6 million)
- Net result: DKK -0.8 million (Q3 2024/2025: DKK -2.0 million)
Year-to-Date
Revenue increased to DKK 6.9 million (DKK 1.6 million) and gross profit to DKK 3.5 million (DKK 1.0 million). Operating result improved to DKK -4.5 million (DKK -7.7 million), and net result improved to DKK -4.5 million (DKK -7.9 million).
Cash Flow and Liquidity
Cash and cash equivalents amounted to DKK 0.4 million at quarter end. Operating cash flow was DKK -3.2 million, mainly reflecting settlement of payables. Additional working-capital financing has been secured and partly received during and after the quarter.
Regulatory Update
Pain Patch and Psoriasis Gel are MDR-approved. Arthritis Gel and Wound Gel are awaiting feedback from the Notified Body, BSI. Regulatory and IP spending is prioritised towards the products and markets with the greatest commercial potential.
Outlook
Management maintains the revenue target for 2025/2026 of DKK 8.0 million. The Board and Management are working on a restructuring of the Group's corporate and capital structure to strengthen the capital base and create a simpler platform for growth. The next milestone is a positive operating result and cash-positive operations.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA A/S is a Danish MedTech company developing IPR-secured, cannabinoid-based medical device products and dermaceutical solutions for pain, skin, sleep, autoimmune and stress-related conditions. Built on a shared deep-tech product platform combining pharmaceutical expertise, advanced ingredients, deposition technology and regulatory know-how, CS MEDICA develops scalable, non-addictive, over-the-counter treatment alternatives for human and veterinary health. The Company’s portfolio includes cosmetics and CE-marked products, approved MDR products and products in MDR transition, supported by patents, trademarks and a commercial footprint across more than 25 countries.. For more information, visit cs-medica.com and LinkedIn.
Tags: